A substantial advancement in diabetes management is emerging with the approval of tirzepatide in a 45mg form. This innovative version builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, and https://bookmarksden.com/story21540131/revolutionary-approach-tirzepatide-strength-for-diabetes-management